FREELINE THERAPEUTICS HOLDIN (FRLN) Stock Price, Forecast & Analysis
NASDAQ:FRLN • US35655L2060
FRLN Key Statistics, Chart & Performance
The current stock price of FRLN is 6.48 USD. In the past month the price increased by 1.25%. In the past year, price decreased by -23.58%.
FRLN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to FRLN. When comparing the yearly performance of all stocks, FRLN turns out to be only a medium performer in the overall market: it outperformed 46.8% of all stocks.
FRLN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FRLN. FRLN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
FRLN Financial Highlights
Over the last trailing twelve months FRLN reported a non-GAAP Earnings per Share(EPS) of -25.95. The EPS decreased by -49.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -101.44% | ||
| ROE | -166.21% | ||
| Debt/Equity | 0 |
FRLN Forecast & Estimates
8 analysts have analysed FRLN and the average price target is 8.41 USD. This implies a price increase of 29.86% is expected in the next year compared to the current price of 6.48.
FRLN Ownership
FRLN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.63 | 403.74B | ||
| AMGN | AMGEN INC | 17.06 | 206.168B | ||
| GILD | GILEAD SCIENCES INC | 16.49 | 183.174B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.69 | 123.671B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.88 | 81.636B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.87 | 43.973B | ||
| INSM | INSMED INC | N/A | 33.829B | ||
| NTRA | NATERA INC | N/A | 29.154B | ||
| BIIB | BIOGEN INC | 12.54 | 28.637B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.16 | 20.386B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FRLN
Company Profile
Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. The company is headquartered in Stevenage, Hertfordshire and currently employs 152 full-time employees. The company went IPO on 2020-08-07. The firm is developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from chronic debilitating diseases. The company uses its rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into a patient’s bloodstream. The company is advancing FLT201, a differentiated gene therapy candidate that delivers a novel transgene, in a Phase 1/2 clinical trial in people with Gaucher disease type 1. Therapeutic AAV vectors consist of two main components: the capsid and the expression cassette (that contains the gene and the promoter). The company has additional programs in research, including one focused on GBA1-linked Parkinson’s disease that leverages the same novel transgene as FLT201.
Company Info
FREELINE THERAPEUTICS HOLDIN
Sycamore House, Gunnels Wood Road, Stevenage
Stevenage HERTFORDSHIRE SG1 2FX GB
CEO: Theresa Heggie
Employees: 152
Phone: 4401438906870
FREELINE THERAPEUTICS HOLDIN / FRLN FAQ
Can you describe the business of FREELINE THERAPEUTICS HOLDIN?
Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. The company is headquartered in Stevenage, Hertfordshire and currently employs 152 full-time employees. The company went IPO on 2020-08-07. The firm is developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from chronic debilitating diseases. The company uses its rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into a patient’s bloodstream. The company is advancing FLT201, a differentiated gene therapy candidate that delivers a novel transgene, in a Phase 1/2 clinical trial in people with Gaucher disease type 1. Therapeutic AAV vectors consist of two main components: the capsid and the expression cassette (that contains the gene and the promoter). The company has additional programs in research, including one focused on GBA1-linked Parkinson’s disease that leverages the same novel transgene as FLT201.
Can you provide the latest stock price for FREELINE THERAPEUTICS HOLDIN?
The current stock price of FRLN is 6.48 USD.
What is the dividend status of FREELINE THERAPEUTICS HOLDIN?
FRLN does not pay a dividend.
What is the ChartMill technical and fundamental rating of FRLN stock?
FRLN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for FRLN stock?
8 analysts have analysed FRLN and the average price target is 8.41 USD. This implies a price increase of 29.86% is expected in the next year compared to the current price of 6.48.
What sector and industry does FREELINE THERAPEUTICS HOLDIN belong to?
FREELINE THERAPEUTICS HOLDIN (FRLN) operates in the Health Care sector and the Biotechnology industry.